Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrovag is a vaginal medical device developed by IBSS Biomed S.A. (Biomed-Lublin) in Poland, formulated as vaginal suppositories (globules). It is designed to alleviate symptoms of vaginal dryness and support the regeneration of the vaginal mucosa. The product contains three key active components: sodium hyaluronate (10 mg), glycogen, and lactic acid. Hydrovag works through a physical mechanism of action by forming a protective, moisturizing coating on the vaginal epithelium, which facilitates tissue repair and helps maintain a physiological acidic pH. It is indicated for vaginal dryness and discomfort caused by estrogen deficiency (particularly during perimenopause), vaginal atrophy, and painful intercourse (dyspareunia). Additionally, it is used to support the recovery of the vaginal epithelium following childbirth, gynecological procedures, or oncological treatments such as radiotherapy and chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hydrovag.